CBFB Antibodies

Core-binding factor subunit beta (CBFB)

Forms the heterodimeric complex core-binding factor (CBF) with RUNX family proteins (RUNX1, RUNX2, and RUNX3). RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', in their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enriches the sequence-specific DNA- binding capacity of RUNX.

The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters. CBF complexes repress ZBTB7B transcription factor during cytotoxic (CD8+) T cell development.

Gene Information

Human
Gene Name:	CBFB
Uniprot:	Q13951
Entrez:	865

Family

Belongs to:
CBF-beta family

Alternative Names

CBFB; CBF-beta; core-binding factor subunit beta; core-binding factor, beta subunit; PEA2-beta; PEBP2B; PEBP2-beta; polyomavirus enhancer binding protein 2, beta subunit; Polyomavirus enhancer-binding protein 2 beta subunit; SL3/AKV core-binding factor beta subunit; SL3-3 enhancer factor 1 beta subunit; SL3-3 enhancer factor 1 subunit beta; SL3-3

Molecular Weight

Mass (kDA):
21.508 kDA

Genomic Context

Human
Location:	16q22.1
Sequence:	16; NC_000016.10 (67029149..67101058)

Subcellular Localizations

Nucleus.

Diseases

• Leukemia
• Leukemia, Myelocytic, Acute
• Myeloid Leukemia
• Chromosome Inversion
• Chromosomal Translocation
• Acute Myelomonocytic Leukemia
• Malignant Neoplasms
• Neoplasms
• Leukemogenesis
• Cytogenetic Abnormality
• Myeloid Leukemia, Chronic
• Myelomonocytic Leukemia

• Eosinophilia
• Neoplasm, Residual
• Acute Lymphocytic Leukemia
• Dysmyelopoietic Syndromes
• Dysplasia
• Cleidocranial Dysplasia
• Lymphoma

Interacting Proteins

• INTS13
• MAP2
• RUNX1

Pathways

• Localization
• Osteoblast Differentiation
• Cell Differentiation
• Bone Development
• Cell Development
• Pathogenesis
• Ossification
• Translation
• Interphase
• Metaphase
• Regeneration
• Cell Death
• Chondrocyte Differentiation

• Reverse Transcription
• Methylation
• Dna Replication
• Cell Adhesion
• Granulocyte Differentiation
• Tube Formation
• Regulation Of Gene Expression

PTMs

• Methylation
• Phosphorylation

• Biotinylation
• Cleavage

• Acetylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/CBFB

Best Uses Of The CBFB Marker

Flow procedures are often a source of confusion and usually have a myriad of options. Boster Bio optimization guidelines and tips can make the process easier. These guides provide tips for optimizing your research and answering the most common questions. You can even follow a step-by-step optimization guide for high-affinity primary antibodies. If you're interested in knowing more about CBFB Marker, read on.

Boster Bio: Steven Boster

The late Don "Steve" Boster, died on July 19 in 2018, at the age of 72. Born in Joliet in Illinois, he worked in Emergency Medicine for 33+ years before making the decision to retire and paint full-time. His studio is located at the Chicken Farm Art Center in San Angelo, Texas. Boster is enthusiastic about animals and his style varies from impressionism and realism from the beginning. He is a lover of vivid colors. Boster is a lifelong hunter and outdoor enthusiast, has made it his goal to give back to the community through his art. Boster donates all profits from every sale to the Fisher House Foundation, which is a non-profit corporation that provides meals to soldiers who are in hospitals and other facilities.

CBFB Marker

The CBFB marker, a tumor suppressor proteins plays a significant role in transcription regulation. When detected in breast cancer cells, the marker boosts the translation of the shuttle protein, which has functions in the nucleus. Although its role in the suppression of breast cancer is not clear, scientists can use it to make better decisions. In addition, it's easy to identify and study in a variety of ways.

Recent studies have revealed that CBFB is a tumor suppressor that plays a role in breast tumor cells. CBFB could also be used to aid in research and treatment by providing researchers the ability to monitor the activity of the protein in cancer cells. However, a potential therapeutic benefit could arise from CBFB's role in translation regulation. In addition to its function in cancer research, CBFB has been found to be an essential molecule involved in the creation of certain hormones.

Primary antibodies with high-affinity

To determine the presence of this protein in a cell lysate we employed an antibody against AF4001a (C-BFB). 35 ug of MCF10A cells were placed on a Lab-Tek II chamber slide. After incubation for 1 hour the cells were washed with PBS three times, and then fixed with the formaldehyde solution of 4. Then, we extracted the total RNA and subjected it to real-time PCR to study the signal.

Primary antibodies are immunoglobulins that recognize epitopes that are unique and have high specificity and high affinity. They can be monoclonal or multiclonal, and are used to detect biomolecules and measuring changes. The spectrum of these antibodies is wide that covers a variety of areas of life science research. To ensure that they perform at the highest level all of them have been rigorously tested. A few of them are already certified for multiple applications.

The CBFB-MYh21 epitope is immunegenic and is recognized by TCR-transduced CD8+ T cells. The epitope is found on the primary AML cells and therefore can be recognized by T cells. In turn, this high-affinity antibody is able to detect CBFB-MYh21 antigens in AML cells. It is an essential step to detect this disease-causing protein within blood cells.

CBFB plays a crucial role in transcription regulation, as well as other kinds of tumors. Although it is difficult to regulate the transcription process in cancer cells, the function of CBFB as a translator may prove useful in the treatment. CBFB also regulates the process of transcription in breast cancer cells. CBFB antibodies have a broad therapeutic potential due to their ability to inhibit the growth of breast cancer cells as well as spread.

The CBFB protein is an epitope in human breast tissue that is not non-neoplastic. The CBFB marker can be used to determine the presence of CBFB in breast tissue. Because the CBFB marker is located in the cells' cytoplasm which is why it is helpful in the detection and treatment of a variety of cancers. High-affinity primary antibodies can be used to detect CBFB in breast cancer in a variety of cancers.

A range of methods have been employed to detect CBFB and other proteins found in human cells. The CBFB marker can be used to detect cells-surface antibodies. A gene expression omnibus database is a new method to utilize genomic data. GSE119131 as well as GSE129314 each contain genomic data, as well as the source data for the Figs. The source data that are corresponding to the Supplementary Figs can be found in the Source Data file.

High-affinity primary antibodies that target the CBFB protein have demonstrated high-affinity binding of both molecules. CBFb-SMMHC D134-236 exhibits a significantly lower binding affinity to RUNX1 than CBFb. This is 100 times more than the wild type. It also significantly decreases the cancer-causing capacity of MCF7 cells. It has also been demonstrated that CBFb suppresses NOTCH3.